CXCL8 and prostate cancer: Moreover, we have also demonstrated that dexamethasone decreases docetaxel-induced CXCL8 secretion from prostate cancer cells and that in vivo, the addition of dexamethasone potentiates the anti-angiogenic activity of docetaxel [126], consistent with the hypothesis that the anti-tumor effects of dexamethasone may be mediated, in part, by the inhibition of stress-induced CXCL8 signaling.